Interestingly, a recent study discovered that treating GSD-1β patients with a sodium glucose cotransporter 2 (SGLT2) inhibitor, an anti-diabetic drug inhibits renal reabsorption of glucose while facilitating excretion of the inhibitory glucose analog, resolving the neutropenia and neutrophil dysfunctions (152). This evidence concerns the gene SLC5A2 and neutropenia.